Thermosome Initiates Final Dose Level in Phase I Trial of Lead Compound THE001
December 04, 2024 04:00 ET
|
AKAMPION
Independent Data Safety Monitoring Board declared dose level 2 as safe and recommended escalation to final dose level 3 Munich, Germany – December 4, 2024 – Thermosome, a drug development company...
Thermosome Presents Encouraging Initial Clinical Data from Phase I Trial of Lead Compound THE001
November 19, 2024 04:00 ET
|
AKAMPION
THE001 safe and well tolerated in first two dose level, demonstrating encouraging signs of clinical activityData presented at The Connective Tissue Oncology Society (CTOS) Annual Meeting 2024 Munich,...
Liposomal Doxorubicin Market Report 2024-2032: Innovative Liposomal Formulations Pave the Way for Safer and More Effective Cancer Treatments
November 07, 2024 08:04 ET
|
Research and Markets
Dublin, Nov. 07, 2024 (GLOBE NEWSWIRE) -- The "Liposomal Doxorubicin Market Report and Forecast 2024-2032" report has been added to ResearchAndMarkets.com's offering.The global liposomal...
$1.89 Bn Liposomal Doxorubicin Markets, 2024-2030: Focus on Doxil/Caelyx, Lipodox, and Myocet
September 30, 2024 05:50 ET
|
Research and Markets
Dublin, Sept. 30, 2024 (GLOBE NEWSWIRE) -- The "Liposomal Doxorubicin Market Size, Share & Trends Analysis Report By Product, By Application (Multiple Myeloma, Ovarian Cancer, Breast Cancer), By...
Doxorubicin Industry Research Report 2024-2030
September 23, 2024 09:54 ET
|
Research and Markets
Dublin, Sept. 23, 2024 (GLOBE NEWSWIRE) -- The "Doxorubicin Market Size, Share & Trends Analysis Report By Drug Formulation (Lyophilized Powder, Doxorubicin Injection), By Application, By...
Doxorubicin Global Strategic Research Report 2024: Market to Reach $1.7 Billion by 2030 from $1.1 Billion in 2023, Driven by Rise in Cancer Incidence and Innovations in Cancer Drug Delivery
April 05, 2024 09:07 ET
|
Research and Markets
Dublin, April 05, 2024 (GLOBE NEWSWIRE) -- The "Doxorubicin - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.Global Doxorubicin Market to Reach $1.7...
Diffuse Large B-Cell Lymphoma Therapeutics Market Forecast to Reach $6.49 Billion by 2028 Amid Advancements in Personalized Medicine and Treatment Innovations
February 08, 2024 09:36 ET
|
Research and Markets
Dublin, Feb. 08, 2024 (GLOBE NEWSWIRE) -- The "Diffuse Large B-cell Lymphoma Therapeutics Global Market Report 2024" has been added to ResearchAndMarkets.com's offering. As the global community...
Triple Negative Breast Cancer Market Analysis and Insights Reveal Dynamic Shifts and Future Growth Projections to 2032
January 24, 2024 10:36 ET
|
Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Triple Negative Breast Cancer (TNBC) - Market Insight, Epidemiology And Market Forecast - 2032" report has been added to ResearchAndMarkets.com's...
Global Thyroid Cancer Drugs Market Report 2024: Highlights Trends in Targeted Therapies, Featuring Profiles of Mylan Pharmaceuticals, AstraZeneca, Exelixis, Pfizer, and Bristol-Myers Squibb
January 23, 2024 15:28 ET
|
Research and Markets
Dublin, Jan. 23, 2024 (GLOBE NEWSWIRE) -- The "Thyroid Cancer Drugs Global Market 2024" report has been added to ResearchAndMarkets.com's offering. The global thyroid cancer drugs market...
Global Thyroid Cancer Drugs Market to Reach $1.29 Billion by 2027: Targeted Therapies Transforming Thyroid Cancer Treatment
July 31, 2023 05:33 ET
|
Research and Markets
Dublin, July 31, 2023 (GLOBE NEWSWIRE) -- The "Thyroid Cancer Drugs Global Market Report 2023" has been added to ResearchAndMarkets.com's offering. This report provides a comprehensive guide to...